Search PubMed⌕ Search

Biomedical subjects

J Sands

Publications and source records attributed to J Sands.

At least 55 records · Page 3Linked to original sources

A comparison of the effects of cytosine arabinoside and adenine arabinoside on some aspects of brain growth and development in the rat.

1. Treatment of pregnant rats with cytosine arabinoside (ara-C, 50 mg/kg, i.p.)at 14 days of gestation severely impaired both prenatal and postnatal whole brain growth in their offspring, although the cerebellum was relatively less affected than whole brain. 2. Rats treated at 5 days of age with ara-C (250 mg/kg, i.p.) showed an impairment in growth of the cerebellum relative to the rest of the brain. 3. Adenine arabinoside (ara-A) treatment, either prenatally or postnatally, had negligible effect on brain growth, even at doses considerably higher than those of ara-C. 4. Adult rats, previously treated with ara-C (50 mg/kg, i.p.) at 14 days of gestation, showed an impairment in discrimination learning when tested in a water T-maze. 5. These results are discussed in relation to the proposed use of ara-C or ara-A as antiviral agents, particularly against intrauterine infection with cytomegalovirus.

Age Factors↗

Continuing growth and development of the third-trimester human placenta.

Two hundred and nineteen human placentae of well ascertained gestational age were measured for weight and nuclear number. Contrary to previous reports, analysis of the results showed no faltering in either parameter, however expressed. The placentae from babies exhibiting intrauterine growth retardation were appropriate to the size of the babies. However else the placenta ages it does not do so in respect of the rate of increase in the number of its nuclei.

Birth Weight↗

The effect of Doppler flow screening studies and elective revisions on dialysis access failure.

A retrospective study was undertaken to see if screening ultrasounds and elective surgical revision could decrease access failure. Two hundred fifty-three accesses [177 gortex grafts, 76 arteriovenous (AV) fistulas] were studied with duplex imaging. Patients were subdivided by access type, flow, percent stenosis, and whether they were surgically revised. Data was examined to determine access failure within 6 months. Ten of 76 fistulas clotted (13.1%), while 53 of 177 grafts clotted (29.9%) (p = 0.005). In Gortex grafts, stenosis (p < 0.05) and decreased flow (p = 0.005) correlated with clotting. In unrevised grafts with flow < or = 801 ml/min, 13 of 14 (92.8%) clotted, whereas of those with flow > or = 1603 ml/min only, 10 of 38 (26.3%) clotted (chi-square = 24.74; p < 0.0001). Only 1 of 18 (5.6%) revised grafts with flow < or = 1300 ml/min clotted, while 29 of 69 (42%) unrevised grafts clotted (p = 0.004). We were unable to demonstrate decreased clotting in fistulae with revisions. In conclusion, screening duplex scanning was able to select groups with a higher risk of access failure over the subsequent 6 months. Elective revision with correction of areas of stenosis in grafts with flows < or = 1300 ml/min significantly decreased the incidence of clotting.

Adult↗

Access flow measured during hemodialysis.

Hemodialysis accesses must supply adequate blood flow to perform hemodialysis and maintain access patency. Access flow (QA) is not measured routinely during hemodialysis. The purpose of this study was to evaluate whether access flow changes during hemodialysis and to determine which factors correlate with QA. The authors measured hemodialysis access flow by ultrasound dilution (QA-T) (Transonic HD01 hemodialysis monitor; Transonic Systems, Inc., Ithaca, NY) and duplex ultrasound, with time-domain correlation (QA-S) (Philips CVI Phillips Medical Systems, Santa Ana, CA) hourly, in 19 patients during hemodialysis. Mean arterial pressure (MAP) (Fresenius automated blood pressure cuff) and cardiac output (CO) (Transonic hemodialysis monitor; Transonic Systems, Inc.) also were measured sequentially. Using duplex ultrasound, access flow was unchanged. However, it fell 132 +/- 137 ml/m (p < 0.05) by ultrasound dilution in hr 4. Cardiac output fell 586 +/- 840 ml/ m (p < 0.05), and MAP fell 11.9 +/- 13.0 mmHg (p < 0.01). There were small positive correlations between CO and QA (correlation coefficient (r) = 0.32, QA-T; r = 0.27, QA-S; p < 0.05), and between CO and MAP (r = 0.35; p < 0.01). In conclusion, access flow, CO, and MAP decreased modestly during hemodialysis. Further studies are necessary to see if access flow is similar off dialysis, and whether in-line access flow measurements can decrease access thrombosis.

Arteriovenous Shunt, Surgical↗

Difference between delivered and prescribed blood flow in hemodialysis.

The authors compared delivered and prescribed blood flow (QB) during 208 hemodialysis treatments using the Transonic hemodialysis monitor (Transonic Systems, Inc, Ithaca, New York). Delivered QB averaged 205.6, 300.6, 384.3 (p < .0001), and 467.7 cc/min (p < .0001) at pump settings of 200, 300, 400, and 500 cc/min. Permcaths had significantly lower delivered QB (188, 266, and 314 cc/min at 200, 300, and 400 pump settings) (p < .01). When catheters were excluded, delivered QB was at least 10% less than prescribed in 13.5%, 18.4%, and 20.8% of patients (300, 400, and 500 pump settings). Patients using 14 gauge arterial needles had higher delivered QB than patients using 15 gauge needles (418 vs 383 cc/min at 400 pump; p < .0001). Patients on Baxter 550 machines had lower delivered QB (294 and 376 ml/min) than those on fresenius 2008H machines (323 and 411 ml/min) at 300 and 400 pump settings, respectively (p < .0001). Excluding catheters, 17.4% and 23.4% of patients on Baxter machines had delivered QB of 10% less than prescribed, compared to 2.1% and 4.3% of patients on Fresenius machines at 300 and 400 pump settings. In conclusion, delivered QB during hemodialysis is often significantly less than prescribed QB. Further studies are necessary to determine the factors involved in these differences.

Arteriovenous Shunt, Surgical↗